Empagliflozin’s clinical endorsement: Revolutionising guidelines across specialties

08 Jun 2020
Empagliflozin’s clinical endorsement: Revolutionising guidelines across specialties
In this third issue we take a look at how empagliflozin made a bold impact on clinical guidelines across multiple specialties. We will explore how existing treatment recommendations were altered, and summarise the current guidelines and future perspectives of empagliflozin’s use.

Related MIMS Drugs

Resources

EMPA_REG OUTCOME: Empagliflozin's clinical endorsement: Revolutionising guidelines across specialties

EMPA_REG OUTCOME: Empagliflozin's clinical endorsement: Revolutionising guidelines across specialties

EMPA_REG OUTCOME: Empagliflozin's clinical endorsement: Revolutionising guidelines across specialties

EMPA_REG OUTCOME: Empagliflozin's clinical endorsement: Revolutionising guidelines across specialties